+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
All Genders
ID05900401

Evaluating Bone Marrow Transplant and Conditioning Therapy to Promote Kidney Transplant Tolerance

Led by Massachusetts General Hospital · Updated on 2026-09-28

20

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of a bone marrow transplant following a kidney transplant from either a living or deceased donor. This trial focuses on recipients who have previously received kidney transplants and are maintained on conventional immunosuppressive therapy. The goal is to protect the transplanted kidney from rejection by the bodys immune system through a conditioning regimen and stem cell infusion. Participants will receive a conditioning treatment including rituximab, fludarabine, cyclophosphamide, local thymic irradiation, and siplizumab before the stem cell transplant. Donor hematopoietic stem cells are infused on the day of transplant. Methylprednisolone is given starting on that day and tapered off by day 20. Prophylactic treatments for infections are provided, and all blood transfusions must be leukocyte-depleted and irradiated for 12 months after transplantation. A kidney biopsy is performed six months after the stem cell transplant, and if criteria are met, immunosuppressive medications are gradually reduced over 9 to 12 months. During the study, participants will undergo close monitoring including laboratory tests and biopsies. Researchers will track outcomes such as the presence of mixed chimerism at 3 months and kidney transplant tolerance up to 2 years after immunosuppression withdrawal. Safety is monitored through tracking survival, graft function, rejection episodes, infections, and other transplant-related complications. The total study duration extends through a follow-up period lasting up to 2 years after stopping immunosuppressive drugs.

CONDITIONS

Brief Title

Delayed Tolerance Through Mixed Chimerism

Research Team

T

Tatsuo Kawai

G

Gabriel Impreso Baysa

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here